A substantial advancement in glucose treatment is emerging with the approval of tirzepatide in a 45mg form. This innovative offering builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and https://socialinplace.com/story6801350/revolutionary-introduction-tirzepatide-45mg-for-glucose-management